Trial name | First author, year | Phase | Masking | Study type | NCT number | QoL measure | ECOG PS | Treatment arms | Follow-up, week |
---|---|---|---|---|---|---|---|---|---|
KEYNOTE-010 [14] | Barlesi F., 2019 | II/III | Open label | RCT | NCT01905657 | EQ-5D-3L, EORTC QLQ-C30 EORTCQLQ-LC13 | 0–1 | Pembrolizumab 2 mg/kg Q3W, pembrolizumab 10 mg/kg Q3W Docetaxel 75 mg/m2 Q3W | 12 |
CheckMate 057 [15] | Reck M., 2018 | III | Open label | RCT | NCT01673867 | LCSS, EQ-5D 3L | 0–1 | Nivolumab 3 mg/kg Q2W Docetaxel 75 mg/m2 Q3W | 66 |
KEYNOTE-024 [16] | Brahme J. R., 2017 | III | Open label | RCT | NCT02142738 | EORTC QLQ-C30 EORTC QLQ-LC13, EQ-5D-3L | 0–1 | Pembrolizumab 200 mg Q3W Five platinum-based chemotherapy regimens Q3W: carboplatin + pemetrexed (500 mg/m2), cisplatin (75 mg/m2) + pemetrexed (500 mg/m2), carboplatin + gemcitabine (1250 mg/m2), cisplatin (75 mg/m2) + gemcitabine (1250 mg/m2), or carboplatin + paclitaxel (200 mg/m2) | 15 |
OAK [17] | Bordoni R., 2018 | III | Open label | RCT | NCT02008227 | EORTCQLQ-C30 EORTC QLQ-LC13. | 0–1 | Atezolizumab 1200 mg Q3W Docetaxel 75 mg/m2 Q3W | 15 |
CheckMate 017 [18] | Reck M., 2017 | III | Open label | RCT | NCT01642004 | LCSS, EQ-5D | 0–1 | Nivolumab 3 mg/kg Q2W Docetaxel 75 mg/m2 Q3W | 60 |
KEYNOTE-407 [19] | Mazieres J., 2018 | III | Double blind | RCT | NCT02775435 | EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-3L | 0–1 | Pembro 200 mg Q3W Pbo Q3W + carboplatin AUC 6 and paclitaxel 200 mg/m2 Q3W or nab-paclitaxel 100 mg/m2 QW | 18 |
PACIFIC [20] | Hui R., 2019 | III | Double blind | RCT | NCT02125461 | EORTC QLQ-C30 EORTC QLQ-LC13, EQ-5D | 0–1 | Durvalumab 10 mg/kg Q2W Matching placebo 1−42 days after chemoradiotherapy | 48 |
EVIDENS [21] | Pero l. M., 2019 | N/A | Double blind | RCT | NCT03382496 | EQ-5D-3L | 0–1 | Nivolumab NA | 36 |
KEYNOTE-189 [22] | Garassino M. C., 2020 | III | Double blind | RCT | NCT02578680 | EORTC QLQ-C30 EORTC QLQ-LC13 | 0–1 | Pembrolizumab (200 mg) or saline placebo Q3W Pemetrexed (500 mg/m2) with carboplatin (5 mg/mL per min) or cisplatin (75 mg/m2, investigator’s choice) Q3W for four cycles, followed by pemetrexed maintenance therapy Q3W | 21 |
MYSTIC (D/D + T) [23] | Garon E. B., 2021 | III | Open label | RCT | NCT02453282 | EORTC QLQ-C30 EORTC QLQ-LC13 | 0–1 | Durvalumab 20 mg/kg Q4W, durvalumab 20 mg/kg Q4W plus tremelimumab 1 mg/kg Q4W Investigator’s choice of platinum-based doublet chemotherapy (four to six cycles) | 24 |